Elicio Therapeutics Sets Nov 12, 2026 Annual Meeting; Shareholder Deadlines

What Happened

• Elicio Therapeutics, Inc. (Form 8‑K filed Sept 14, 2026) announced that its 2026 annual meeting of stockholders will be held on November 12, 2026. The company said it will provide the exact time, location and matters to be voted on in its forthcoming proxy statement.
• Because the meeting date moves more than 30 and 60 days from the prior anniversary date, the Board set a single deadline of September 24, 2026 for (a) stockholder proposals submitted under SEC Rule 14a‑8 to be included in the company’s proxy materials and (b) timely notice under the company’s Amended and Restated Bylaws for director nominations or other matters to be considered at the meeting. Stockholders intending to solicit proxies supporting nominees other than the company’s must also meet the Rule 14a‑19 (universal proxy) notice requirements by September 24, 2026.

Key Details

• Annual meeting date: November 12, 2026.
• Deadlines for shareholder actions: September 24, 2026 for Rule 14a‑8 proposals, by‑law nominations, and Rule 14a‑19 universal proxy notices.
• Principal executive office address for submitting notices: 451 D Street, 5th Floor, Boston, Massachusetts 02210.
• 8‑K signed by Robert Connelly (President & CEO) on September 14, 2026.

Why It Matters

• If you plan to submit a proposal or nominate a director at Elicio’s 2026 annual meeting, you must meet the September 24, 2026 deadlines and comply with SEC rules and the company’s bylaws or your item may be excluded from the proxy materials.
• The announcement sets the procedural timeline for shareholder engagement and proxy contests; investors should watch for the company’s proxy statement for final agenda items, voting details and logistics.